TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer
NCT ID: NCT05284994
Last Updated: 2022-03-17
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE1/PHASE2
Total Enrollment
160 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-03-11
Study Completion Date
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
TQ-B3525 tablet is a new α/δ dual inhibitor phosphatidylinositol 3-kinase inhibitor developed by Chia Tai Tianqing pharmaceutical Group Co., Ltd. It can overcome the drug resistance problem caused by the up-regulation of phosphatidylinositol 3-kinase α subunit activity caused by the single inhibition of phosphatidylinositol 3-kinase δ subunit. This study is a single-arm, open-label, multi-cohort, multi-center clinical study of the safety and efficacy of TQ-B3525 tablets combined with osimertinib in subjects with advanced non-small cell lung cancer, aiming to evaluate TQ-B3525 tablets combined with osimertinib, the safety, tolerability, and efficacy of the treatment of patients with advanced non-small cell lung cancer who have failed epidermal growth factor receptor inhibitor therapy, while exploring the efficacy, resistance mechanism, and safety in the dose escalation phase biomarkers.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
NCT03972189
ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
UNKNOWN
PHASE2
Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers
NCT06585059
Advanced Non-small Cell Lung Cancer
NOT_YET_RECRUITING
PHASE1
Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
NCT04056572
ALK-positive NSCLC
UNKNOWN
PHASE2
Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)
NCT04009317
ALK-positive NSCLC
UNKNOWN
PHASE3
A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer
NCT04398940
Non Small Cell Lung Cancer
UNKNOWN
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Nonsmall-cell Lung Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TQ-B3525 Tablets + Osimertinib Mesylate Tablets.
TQ-B3525 tablets combined with osimertinib mesylate tablets, 30 days as a treatment cycle.
Group Type
OTHER
TQ-B3525 Tablets, Osimertinib Mesylate Tablets
Intervention Type
DRUG
TQ-B3525 is a novel α/δ dual inhibitor PI3K kinase inhibitor. Osimertinib mesylate is a third-generation epidermal growth factor receptor inhibitor.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TQ-B3525 Tablets, Osimertinib Mesylate Tablets
TQ-B3525 is a novel α/δ dual inhibitor PI3K kinase inhibitor. Osimertinib mesylate is a third-generation epidermal growth factor receptor inhibitor.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 1 Aged 18 to 75 years old, and gender is not limited.
* 2 The eastern cooperative oncology group（ECOG）score is 0 to 1, and the expected survival time is greater than or equal to 12 weeks.
* 3 Subjects with histologically or cytologically confirmed non-small cell lung cancer (NSCLC) and stage IIIB-IV (according to the 8th edition of the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer Classification).
* 4 The enrollment requirements for the dose escalation phase are as follows:
1. Patients who have failed previous standard therapy, including disease progression or toxicity intolerance, or who are clinically unsuitable or unacceptable, or who refuse to receive standard therapy.
2. The test report can reflect the presence of epidermal growth factor receptor (EGFR) sensitive mutations when the subjects were enrolled in this trial.
3. Requirements for meeting the epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment failure criteria:
1. Subjects without T790M mutation after receiving first- or second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment resistance in the past; or subjects who have previously received third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment resistance.
2. According to the definition of response evaluation criteria in solid tumors Recist version 1.1 (Recist 1.1) criteria, disease progression occurs after continuous epidermal growth factor receptor- -tyrosine kinase inhibitor treatment for at least 1 month.
3. No other systemic therapy between discontinuation of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) and initiation of new therapy.
* 5 The enrollment requirements for Cohort 1 in the dose expansion phase are as follows:
1. failure of previous standard therapy, including disease progression or toxicity intolerance, or clinical inappropriateness/inability to accept/refusal to receive standard therapy.
2. There is a sensitive epidermal growth factor receptor（EGFR） mutation, and previous reports have confirmed that it is accompanied by a gene abnormality in the PI3K signaling pathway.
3. Requirements for meeting the epidermal growth factor receptor-tyrosine kinase inhibitor（EGFR-TKI）treatment failure criteria:
1. Subjects without T790M mutation after receiving first- or second-generation epidermal growth factor receptor-tyrosine kinase inhibitor（EGFR-TKI） treatment resistance in the past; or subjects who have previously received third-generation epidermal growth factor receptor-tyrosine kinase inhibitor（EGFR-TKI）treatment resistance.
2. According to the definition of response evaluation criteria in solid tumors Recist version 1.1(Recist 1.1)criteria, disease progression occurs after continuous epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI) treatment for at least 1 month.
3. No other systemic therapy between discontinuation of epidermal growth factor receptor-tyrosine kinase inhibitor（EGFR-TKI）and initiation of new therapy.
* 6 Enrollment requirements for Cohort 2 in the dose expansion phase are as follows:
1. failure of previous standard therapy, including disease progression or toxicity intolerance, or clinically inappropriate, or unacceptable, or refusal to receive standard therapy.
2. There is a sensitive epidermal growth factor receptor（EGFR） mutation, and previous reports have confirmed that there is no abnormality in the PI3K signaling pathway, and the report can reflect the gene status of the subjects when they are enrolled in this trial.
3. Meet the following definitions for epidermal growth factor receptor-tyrosine kinase inhibitor（EGFR-TKI）treatment failure:
1. Subjects without T790M mutation after receiving first- or second-generation epidermal growth factor receptor-tyrosine kinase inhibitor（EGFR-TKI） treatment resistance in the past; or subjects who have previously received third-generation epidermal growth factor receptor-tyrosine kinase inhibitor（EGFR-TKI）treatment resistance.
2. According to the definition of response evaluation criteria in solid tumors Recist version 1.1（Recist 1.1）criteria, disease progression occurs after continuous epidermal growth factor receptor-tyrosine kinase inhibitor（EGFR-TKI） treatment for at least 1 month.
3. No other systemic therapy between discontinuation of epidermal growth factor receptor-tyrosine kinase inhibitor（EGFR-TKI）and initiation of new therapy.
* 7 The enrollment requirements for Cohort 3 in the dose expansion phase are as follows.
1. Have not received any systemic therapy for locally advanced or metastatic NSCLC before.
2. There are epidermal growth factor receptor（EGFR） sensitive mutations, and the test report can reflect the gene status of the subjects when they are enrolled in this trial.
* 8 At the time of screening, according to response evaluation criteria in solid tumors Recist version 1.1（Recist 1.1）criteria, the patient has at least one measurable target lesion.
* 9 Inspections during the screening period shall meet the following conditions:
1. The absolute value of neutrophils (ANC) is greater than or equal to 1.5×109/L.
2. Platelet count (PLT) greater than or equal to 75×109/L.
3. Hemoglobin is greater than or equal to 90g/L.
4. The total blood bilirubin is less than or equal to 1.5 times the upper limit of normal（ULN）. If it is a subject with Gilbert syndrome, the total blood bilirubin is less than or equal to 3×upper limit of normal（ULN）.
5. Serum creatinine (Cr) is less than or equal to 1.5×upper limit of normal（ULN）, or creatinine clearance rate is greater than or equal to 60ml/min.
6. alanine aminotransferase（ALT）and aspartate aminotransferase（AST）are less than or equal to 2.5 times upper limit of normal（ULN）. If there is liver metastasis, alanine aminotransferase（ALT）and aspartate aminotransferase（AST）can be relaxed to the corresponding 5 times upper limit of normal（ULN）.
7. Coagulation function tests must meet the following criteria: prothrombin time (PT), activated partial thromboplastin time (APTT), and international normalized ratio (INR) are all less than or equal to 1.5 times the upper limit of normal (ULN) coagulation therapy) .
8. Doppler ultrasound: left ventricular ejection fraction (LVEF) greater than or equal to 50%.
* 10 The subjects voluntarily participated in this study and signed the informed consent.
* 2 The eastern cooperative oncology group（ECOG）score is 0 to 1, and the expected survival time is greater than or equal to 12 weeks.
* 3 Subjects with histologically or cytologically confirmed non-small cell lung cancer (NSCLC) and stage IIIB-IV (according to the 8th edition of the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer Classification).
* 4 The enrollment requirements for the dose escalation phase are as follows:
1. Patients who have failed previous standard therapy, including disease progression or toxicity intolerance, or who are clinically unsuitable or unacceptable, or who refuse to receive standard therapy.
2. The test report can reflect the presence of epidermal growth factor receptor (EGFR) sensitive mutations when the subjects were enrolled in this trial.
3. Requirements for meeting the epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment failure criteria:
1. Subjects without T790M mutation after receiving first- or second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment resistance in the past; or subjects who have previously received third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment resistance.
2. According to the definition of response evaluation criteria in solid tumors Recist version 1.1 (Recist 1.1) criteria, disease progression occurs after continuous epidermal growth factor receptor- -tyrosine kinase inhibitor treatment for at least 1 month.
3. No other systemic therapy between discontinuation of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) and initiation of new therapy.
* 5 The enrollment requirements for Cohort 1 in the dose expansion phase are as follows:
1. failure of previous standard therapy, including disease progression or toxicity intolerance, or clinical inappropriateness/inability to accept/refusal to receive standard therapy.
2. There is a sensitive epidermal growth factor receptor（EGFR） mutation, and previous reports have confirmed that it is accompanied by a gene abnormality in the PI3K signaling pathway.
3. Requirements for meeting the epidermal growth factor receptor-tyrosine kinase inhibitor（EGFR-TKI）treatment failure criteria:
1. Subjects without T790M mutation after receiving first- or second-generation epidermal growth factor receptor-tyrosine kinase inhibitor（EGFR-TKI） treatment resistance in the past; or subjects who have previously received third-generation epidermal growth factor receptor-tyrosine kinase inhibitor（EGFR-TKI）treatment resistance.
2. According to the definition of response evaluation criteria in solid tumors Recist version 1.1(Recist 1.1)criteria, disease progression occurs after continuous epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI) treatment for at least 1 month.
3. No other systemic therapy between discontinuation of epidermal growth factor receptor-tyrosine kinase inhibitor（EGFR-TKI）and initiation of new therapy.
* 6 Enrollment requirements for Cohort 2 in the dose expansion phase are as follows:
1. failure of previous standard therapy, including disease progression or toxicity intolerance, or clinically inappropriate, or unacceptable, or refusal to receive standard therapy.
2. There is a sensitive epidermal growth factor receptor（EGFR） mutation, and previous reports have confirmed that there is no abnormality in the PI3K signaling pathway, and the report can reflect the gene status of the subjects when they are enrolled in this trial.
3. Meet the following definitions for epidermal growth factor receptor-tyrosine kinase inhibitor（EGFR-TKI）treatment failure:
1. Subjects without T790M mutation after receiving first- or second-generation epidermal growth factor receptor-tyrosine kinase inhibitor（EGFR-TKI） treatment resistance in the past; or subjects who have previously received third-generation epidermal growth factor receptor-tyrosine kinase inhibitor（EGFR-TKI）treatment resistance.
2. According to the definition of response evaluation criteria in solid tumors Recist version 1.1（Recist 1.1）criteria, disease progression occurs after continuous epidermal growth factor receptor-tyrosine kinase inhibitor（EGFR-TKI） treatment for at least 1 month.
3. No other systemic therapy between discontinuation of epidermal growth factor receptor-tyrosine kinase inhibitor（EGFR-TKI）and initiation of new therapy.
* 7 The enrollment requirements for Cohort 3 in the dose expansion phase are as follows.
1. Have not received any systemic therapy for locally advanced or metastatic NSCLC before.
2. There are epidermal growth factor receptor（EGFR） sensitive mutations, and the test report can reflect the gene status of the subjects when they are enrolled in this trial.
* 8 At the time of screening, according to response evaluation criteria in solid tumors Recist version 1.1（Recist 1.1）criteria, the patient has at least one measurable target lesion.
* 9 Inspections during the screening period shall meet the following conditions:
1. The absolute value of neutrophils (ANC) is greater than or equal to 1.5×109/L.
2. Platelet count (PLT) greater than or equal to 75×109/L.
3. Hemoglobin is greater than or equal to 90g/L.
4. The total blood bilirubin is less than or equal to 1.5 times the upper limit of normal（ULN）. If it is a subject with Gilbert syndrome, the total blood bilirubin is less than or equal to 3×upper limit of normal（ULN）.
5. Serum creatinine (Cr) is less than or equal to 1.5×upper limit of normal（ULN）, or creatinine clearance rate is greater than or equal to 60ml/min.
6. alanine aminotransferase（ALT）and aspartate aminotransferase（AST）are less than or equal to 2.5 times upper limit of normal（ULN）. If there is liver metastasis, alanine aminotransferase（ALT）and aspartate aminotransferase（AST）can be relaxed to the corresponding 5 times upper limit of normal（ULN）.
7. Coagulation function tests must meet the following criteria: prothrombin time (PT), activated partial thromboplastin time (APTT), and international normalized ratio (INR) are all less than or equal to 1.5 times the upper limit of normal (ULN) coagulation therapy) .
8. Doppler ultrasound: left ventricular ejection fraction (LVEF) greater than or equal to 50%.
* 10 The subjects voluntarily participated in this study and signed the informed consent.
Exclusion Criteria
* 1 There are contraindications to Osimertinib Mesylate Tablets administration.
* 2 Other malignant tumors that have occurred or are currently at the same time within 3 years, except for cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumor.
* 3 The subject has received PI3K inhibitor treatment in the past.
* 4 Subjects who have received other systemic anti-tumor drugs within 3 weeks before the first dose, or who are still within the in 5 half-life period of the drug.
* 5 Received any major surgical treatment within 4 weeks before the first dosage.
* 6 Received any previous radiotherapy for curative purposes within 2 weeks before the first drug.
* 7 Unrelieved toxic reactions higher than common terminology criteria for adverse events （CTC AE）grade 1 due to any previous treatment, excluding alopecia.
* 8 The subjects had active serious viral, or bacterial, or fungal infections within 4 weeks before the first administration.
* 9 One of the following conditions of grade II or above occurred within 6 months before the first medication: myocardial infarction, severe or unstable angina pectoris, coronary or peripheral artery bypass grafting, cerebrovascular accident, including transient cerebral ischemia attack, as well as deep vein thrombosis or pulmonary embolism.
* 10 Current uncontrolled congestive heart failure.
* 11 Currently there is persistent arrhythmia greater than or equal to grade II, any degree of uncontrolled atrial fibrillation or QTc interval greater than 480 ms.
* 12 Subjects with unsatisfactory blood pressure control, that is, subjects with systolic blood pressure greater than or equal to 150 mmHg and diastolic blood pressure greater than or equal to 100 mmHg.
* 13 Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage.
* 14 Type I and type II diabetes, in addition to only taking exercise and diet control, or only needing a single oral hypoglycemic drug to stably control blood sugar, and fasting blood sugar less than 7.0 mmol/L and glycosylated hemoglobin (HbA1c) less than 7.0 during the screening period % of subjects with type II diabetes.
* 15 Presence of interstitial lung disease, severely impaired lung function, severe pulmonary fibrosis, radiation pneumonitis, history of drug-induced lung disease, and evidence of active pulmonary inflammation on chest computed tomography (CT) findings during screening.
* 16 Subjects with a history of immunodeficiency, including but not limited to HIV-positive or other acquired, congenital immunodeficiency diseases, or subjects with active autoimmune diseases or a history of autoimmune diseases.
* 17 There is currently a severe and unstable central nervous system metastasis. Note: Patients with no or mildly symptomatic central nervous system（CNS）metastases can be included. Whole brain radiation or gamma knife therapy received due to central nervous system（CNS）metastases must be completed 14 days before the first dose and clinically stable.
* 18 When virological testing during the screening period shows any of the following:
1. hepatitis B surface antigen（HBsAg）positive and hepatitis B virus Deoxyribonucleic acid（HBV-DNA）exceeding the upper limit of normal or hepatitis B virus Deoxyribonucleic acid（HBV-DNA）exceeding 1000copies/ml.
2. Anti- hepatitis C virus（HCV）positive and hepatitis C virus（HCV）ribonucleic acid（RNA）positive or beyond the upper limit of normal.
* 19 People with multiple factors that affect oral administration and drug absorption, such as inability to swallow, post gastrointestinal resection, ulcerative colitis, symptomatic or inflammatory bowel disease, chronic diarrhea and intestinal obstruction and other gastrointestinal diseases.
* 20 Women of childbearing age have a positive pregnancy test before administration of the study drug, or who cannot guarantee to take effective contraceptive measures during the study period, and men cannot guarantee to take effective contraceptive measures during the study period.
* 21 Any other circumstances that are judged by the investigator to be incapable of being included in the study.
* 2 Other malignant tumors that have occurred or are currently at the same time within 3 years, except for cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumor.
* 3 The subject has received PI3K inhibitor treatment in the past.
* 4 Subjects who have received other systemic anti-tumor drugs within 3 weeks before the first dose, or who are still within the in 5 half-life period of the drug.
* 5 Received any major surgical treatment within 4 weeks before the first dosage.
* 6 Received any previous radiotherapy for curative purposes within 2 weeks before the first drug.
* 7 Unrelieved toxic reactions higher than common terminology criteria for adverse events （CTC AE）grade 1 due to any previous treatment, excluding alopecia.
* 8 The subjects had active serious viral, or bacterial, or fungal infections within 4 weeks before the first administration.
* 9 One of the following conditions of grade II or above occurred within 6 months before the first medication: myocardial infarction, severe or unstable angina pectoris, coronary or peripheral artery bypass grafting, cerebrovascular accident, including transient cerebral ischemia attack, as well as deep vein thrombosis or pulmonary embolism.
* 10 Current uncontrolled congestive heart failure.
* 11 Currently there is persistent arrhythmia greater than or equal to grade II, any degree of uncontrolled atrial fibrillation or QTc interval greater than 480 ms.
* 12 Subjects with unsatisfactory blood pressure control, that is, subjects with systolic blood pressure greater than or equal to 150 mmHg and diastolic blood pressure greater than or equal to 100 mmHg.
* 13 Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage.
* 14 Type I and type II diabetes, in addition to only taking exercise and diet control, or only needing a single oral hypoglycemic drug to stably control blood sugar, and fasting blood sugar less than 7.0 mmol/L and glycosylated hemoglobin (HbA1c) less than 7.0 during the screening period % of subjects with type II diabetes.
* 15 Presence of interstitial lung disease, severely impaired lung function, severe pulmonary fibrosis, radiation pneumonitis, history of drug-induced lung disease, and evidence of active pulmonary inflammation on chest computed tomography (CT) findings during screening.
* 16 Subjects with a history of immunodeficiency, including but not limited to HIV-positive or other acquired, congenital immunodeficiency diseases, or subjects with active autoimmune diseases or a history of autoimmune diseases.
* 17 There is currently a severe and unstable central nervous system metastasis. Note: Patients with no or mildly symptomatic central nervous system（CNS）metastases can be included. Whole brain radiation or gamma knife therapy received due to central nervous system（CNS）metastases must be completed 14 days before the first dose and clinically stable.
* 18 When virological testing during the screening period shows any of the following:
1. hepatitis B surface antigen（HBsAg）positive and hepatitis B virus Deoxyribonucleic acid（HBV-DNA）exceeding the upper limit of normal or hepatitis B virus Deoxyribonucleic acid（HBV-DNA）exceeding 1000copies/ml.
2. Anti- hepatitis C virus（HCV）positive and hepatitis C virus（HCV）ribonucleic acid（RNA）positive or beyond the upper limit of normal.
* 19 People with multiple factors that affect oral administration and drug absorption, such as inability to swallow, post gastrointestinal resection, ulcerative colitis, symptomatic or inflammatory bowel disease, chronic diarrhea and intestinal obstruction and other gastrointestinal diseases.
* 20 Women of childbearing age have a positive pregnancy test before administration of the study drug, or who cannot guarantee to take effective contraceptive measures during the study period, and men cannot guarantee to take effective contraceptive measures during the study period.
* 21 Any other circumstances that are judged by the investigator to be incapable of being included in the study.
Minimum Eligible Age
18 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sun-Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
Site Status
RECRUITING
Sun Yat-Sen Memorial Hospital
Guangzhou, Guangdong, China
Site Status
RECRUITING
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Site Status
RECRUITING
Southern Hospital of Southern Medical University
Guangzhou, Guangdong, China
Site Status
RECRUITING
The First Affiliated Hospital of Guangdong Pharmaceutical University
Guangzhou, Guangdong, China
Site Status
RECRUITING
The Second People's Hospital of Guangdong Province
Guanzhou, Guangdong, China
Site Status
RECRUITING
Jiangmen Central Hospital
Jiangmen, Guangdong, China
Site Status
RECRUITING
Meizhou People's Hospital
Meizhou, Guangdong, China
Site Status
RECRUITING
Affiliated Hospital Of Guangdong Medical University
Zhanjiang, Guangdong, China
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
China
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TQ-B3525-Ib/II -01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
NCT03255083
TERMINATED
PHASE1
Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M
NCT04029350
UNKNOWN
PHASE2
SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.
NCT05020769
ACTIVE_NOT_RECRUITING
PHASE2/PHASE3
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
NCT05382728
RECRUITING
PHASE3
A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer
NCT01874678
COMPLETED
NA
Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations
NCT05507606
UNKNOWN
PHASE2
A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients
NCT03485326
COMPLETED
A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations
NCT06362980
RECRUITING
PHASE1
Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC
NCT03133234
COMPLETED
Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
NCT02959749
COMPLETED
PHASE2/PHASE3
Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations
NCT04695925
ACTIVE_NOT_RECRUITING
PHASE3
Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive
NCT07063329
NOT_YET_RECRUITING
PHASE1/PHASE2
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
NCT07181499
RECRUITING
PHASE2
Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency
NCT02062515
UNKNOWN
PHASE2
Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer
NCT04073537
UNKNOWN
PHASE3
A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer
NCT04619537
UNKNOWN
PHASE2
Selumetinib in Combination With Gefitinib in NSCLC Patients
NCT02025114
COMPLETED
PHASE1/PHASE2
A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations
NCT05801029
ACTIVE_NOT_RECRUITING
PHASE2
Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR
NCT01744925
UNKNOWN
PHASE2
A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
NCT06254599
NOT_YET_RECRUITING
PHASE3
An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer
NCT03129256
COMPLETED
PHASE2
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
NCT05009836
ACTIVE_NOT_RECRUITING
PHASE3
Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC
NCT05011487
RECRUITING
PHASE2